Anzeige
Mehr »
Mittwoch, 01.04.2026 - Börsentäglich über 12.000 News
Kritische Rohstoffe: China verknappt Germanium - und diese Aktie könnte zum westlichen Schlüsselspieler werden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

NASDAQ Biotech 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im NASDAQ Biotech

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
16:06Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday1
16:06Why Is Caris Life Sciences Stock Gaining Wednesday?1
15:59Vertex Wins FDA Nod for Cystic Fibrosis Treatment7
15:42Genmab Appoints Margarida Duarte as GM, Europe and Emerging Markets2
15:34Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?1
14:58Tempus AI-Studie: Automatisierte Warnmeldungen verbessern Behandlung von Herzklappenerkrankungen7
14:54Tempus AI trial shows automated alerts improve heart valve care3
14:46Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa4
14:30Vertex Pharma wins FDA label expansion for cystic fibrosis therapies5
14:30Ardelyx names Rajani Dinavahi as chief medical officer1
14:30Janux Therapeutics receives $35M milestone from Bristol Myers Squibb4
14:29Ardelyx Appoints Rajani Dinavahi As Chief Medical Officer1
14:22Ardelyx ernennt Rajani Dinavahi zur neuen Chief Medical Officer1
14:22Janux Therapeutics erhält Meilensteinzahlung in Höhe von 35 Millionen US-Dollar von Bristol Myers Squibb3
14:18Biogen stock price target raised to $245 by Canaccord on Apellis deal3
14:06Ardelyx, Inc.: Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx98WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...
► Artikel lesen
14:06Cantor Fitzgerald reiterates Ascendis Pharma stock rating at overweight1
14:06Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)199Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination...
► Artikel lesen
14:00Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda127TOKYO (dpa-AFX) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063...
► Artikel lesen
13:59Agios mulls early FDA filing for sickle cell therapy-
Weiter >>